News

Business Wire6y
Forbius: First Patient Dosed in a Phase 1b Myelofibrosis Trial of AVID200, a Novel TGF-beta 1 & 3 Inhibitor - Business Wire
Forbius announced that the first patient has been dosed in a Phase 1b trial assessing AVID200 in patients with in patients with myelofibrosis (MF).
Business Wire3y
PeptiGrowth Inc. Is Launching A Novel Synthetic Peptide TGFβ1 Inhibitor, Following Its First Product HGF Alternative Peptide - Business Wire
Following HGF Alternative Peptide and TGFβ1 inhibitor, PeptiGrowth is planning to launch the next product by the end of March, 2022. Details will be updated on its website upon release. Contacts ...
ascopubs.org5y
Safety and preliminary antitumor activity of the transforming growth factor beta (TGF-β) receptor I kinase inhibitor, vactosertib, in combination with ... - ASCO Publications
Background: Recent studies demonstrated that TGF-β signaling attenuation in combination with paclitaxel inhibits epithelial-to-mesenchymal transition and cancer stem-like cells features, especially in ...
FiercePharma10y
Rigel and Bristol-Myers Squibb Announce Research and Development Collaboration for TGF Beta Receptor Kinase Inhibitors for Use in Immuno-Oncology Related Indications
Rigel and Bristol-Myers Squibb Announce Research and Development Collaboration for TGF Beta Receptor Kinase Inhibitors for Use in Immuno-Oncology Related Indications. Feb 24, 2015 3:00am.
FierceBiotech10y
Rigel and Bristol-Myers Squibb Announce Research and Development Collaboration for TGF Beta Receptor Kinase Inhibitors for Use in Immuno-Oncology Related Indications
Category: Partnering News, R&D News Monday, February 23, 2015 8:00 am EST "This collaboration places our TGF beta receptor kinase inhibitor program into the hands of Bristol-Myers Squibb, a ...